For this purpose, correlation of PEA-15 phosphorylation with therapy outcome in high-grade serous ovarian cancer is needed, as this subtype is the most aggressive and has the worst prognosis [59]. This evidence concerns the gene PEA15 and ovarian serous adenocarcinoma.